



Arrotex partners with Celltrion to launch two first-to-market biosimilars in Australia

Delivering key growth through our platform in community pharmacy

1 August 2025

Arrotex Pharmaceuticals has entered into a strategic agreement with Celltrion Healthcare Australia [Celltrion] to launch two new first-to-market biosimilar medicines – with both medicines listed on the Australian Pharmaceutical Benefits Scheme (PBS) and available in pharmacies from today for a range of chronic inflammatory conditions.

This new partnership will deliver a compelling combination for Australian healthcare. We are licensing two of Celltrion's world-class biosimilar treatments, bringing increased value to clinicians and their patients through our extensive platform in community pharmacy.

Celltrion will engage with key prescribing physicians, including gastroenterologists and respiratory specialists, while our team will be the exclusive distribution partner in Australia for the pair of brands – covering community pharmacy distribution as well as representation across the dermatology segment.

Currently, 8.7 million Australians are estimated to be living with chronic inflammatory conditions – including plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, severe asthma, severe allergic asthma, and severe chronic spontaneous urticaria, among others. Approximately 8,000 Australians are newly diagnosed with these often-debilitating conditions every year.

Adam Kelly, Arrotex's Head of Pharmaceutical Sales said of the partnership, "As Australia's leading biosimilars provider, we are proud to offer two first-to-market biosimilar medicines, leveraging our strong presence in community pharmacy."